Gene therapy for X-linked myotubular myopathy: the challenges
- PMID: 37977700
- DOI: 10.1016/S1474-4422(23)00416-7
Gene therapy for X-linked myotubular myopathy: the challenges
Erratum in
-
Correction to Lancet Neurol 2023; 22: 1089-91.Lancet Neurol. 2024 Feb;23(2):e2. doi: 10.1016/S1474-4422(23)00511-2. Lancet Neurol. 2024. PMID: 38267193 No abstract available.
Conflict of interest statement
NCV was Principal Investigator of the Unite-CNM trial on Dynacure, and is a member of the scientific advisory board of ZNM Zusammen Stark!. HJ has acted in an advisory capacity for Audentes and Astellas, two companies involved in the development of treatments for X-linked myotubular myopathy. AAR and AF declare no competing interests. All authors are members of the European Reference Network for rare neuromuscular diseases. The authors are grateful to all patients and their families who participated in the natural history studies and the ASPIRO trial, and to the international patient organisations ZNM Zusammen Stark!, the Myotubular Trust, and the MTM-CNM Family Connection.
Comment on
-
Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial.Lancet Neurol. 2023 Dec;22(12):1125-1139. doi: 10.1016/S1474-4422(23)00313-7. Lancet Neurol. 2023. PMID: 37977713 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources